Morepen Laboratories Limited has informed the Exchange regarding Appointment of Mr PD and Associates as Other of the company w.e.f. April 01, 2025.
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Morepen Laboratories' board approved Q1 FY26 (ended June 30, 2025) consolidated results: total income fell to Rs. 42,964.73 lakhs from Rs. 45,864.27 lakhs a year ago, while net profit after minority interest dropped sharply to Rs. 1,074.83 lakhs from Rs. 3,616.79 lakhs, with EPS at Rs. 0.20 versus Rs. 0.71. Standalone net profit stood at Rs. 806.12 lakhs (down from Rs. 3,504.96 lakhs). The board set August 30, 2025 as the record date for the final dividend for FY25, subject to AGM approval. It also sought shareholder approval to extend the timeline for hiving off its Medical Devices Business into subsidiary Morepen Medipath Limited on a slump sale basis. Mr. Sanjay Suri (promoter group member and brother of CMD Sushil Suri) was re-appointed as Whole-Time Director for three more years, and M/s. PD and Associates was appointed as Secretarial Auditor for five years (FY26-FY30). The 40th AGM is scheduled for September 6, 2025.
Sharply weaker Q1 profits (down roughly 70% year-on-year) despite only a modest revenue decline are a negative signal for near-term sentiment, while the medical devices hive-off and promoter-family director continuity indicate ongoing restructuring. Shareholders eligible on the August 30 record date stand to receive the FY25 final dividend, pending AGM approval.